<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735083</url>
  </required_header>
  <id_info>
    <org_study_id>CL1-68587-003</org_study_id>
    <secondary_id>2016-000297-38</secondary_id>
    <nct_id>NCT02735083</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19</brief_title>
  <official_title>Long-term Follow-up Study of Patients Who Have Previously Been Exposed to UCART19 (Allogeneic Engineered T-cells Expressing a Lentiviral-based Anti-CD19 Chimeric Antigen Receptor)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and efficacy of UCART 19
      administration to patients with advanced lymphoid malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 9, 2016</start_date>
  <completion_date type="Anticipated">March 2040</completion_date>
  <primary_completion_date type="Anticipated">March 2040</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety of UCART19</measure>
    <time_frame>Up to 15 Year</time_frame>
    <description>Number, duration, outcome of all adverse events (AE) within 12 months after allo-HSCT (if performed), or within 12 months after D84 post UCART19 infusion
Number, duration, outcome of adverse events of special interest (AESI) and any AE assessed as related to UCART19 up to the end of the study
For paediatric patients: assesment of the potential impact on growth curve and puberty</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of long-term anti leukemic activity of UCART19.</measure>
    <time_frame>Month 3, Month 6, Month 12 during Year 1 following UCART19 dosing, then every 6 months up to Year 3, then yearly up to Year 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who underwent allogeneic HSCT (Hematopoietic Stem Cell Transplantation)</measure>
    <time_frame>Month 3, Month 6, Month 12 during Year 1 following UCART19 dosing, then every 6 months up to Year 3, then yearly up to Year 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to transplant</measure>
    <time_frame>Month 3, Month 6, Month 12 during Year 1 following UCART19 dosing, then every 6 months up to Year 3, then yearly up to Year 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with detectable UCART19 levels in blood</measure>
    <time_frame>Month 3, Month 6, Month 12 during Year 1 following UCART19 dosing, then every 6 months up to Year 3, then yearly up to Year 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with detectable UCART19 levels in bone marrow</measure>
    <time_frame>Month 3, Month 6, Month 12 during Year 1 following UCART19 dosing, then every 6 months up to Year 3, then yearly up to Year 15</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Advanced Lymphoid Malignancies</condition>
  <arm_group>
    <arm_group_label>UCART19 follow-up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>UCART19 follow-up</intervention_name>
    <description>UCART19 will not be administered during the study period. All patients who have previously received UCART19 will be rolled-over to this long term follow-up study at the end of the parent study or at any time after UCART19 administration in case of premature discontinuation from the parent study.</description>
    <arm_group_label>UCART19 follow-up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained prior any study-specific procedure (patient or
             parent(s) or legal representative)

          -  Patient dosed with UCART19 who completed or discontinued early from a sponsored or
             from any investigator-initiated study that tested UCART19, or patients who were
             administered UCART19 under a special access scheme (compassionate use);

          -  Female patients of childbearing potential and male patients with partners of
             childbearing potential must continue to use an effective method of birth control as
             well as their partners.

        Exclusion Criteria:

        - No exclusion criteria for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reuben Benjamin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachussetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Het Kinderziekenhuis Prinses Elisabeth - UZG</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>PARIS Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert-Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Great Ormond Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.servier.com</url>
    <description>Find Results on Servier Clinical Trial Data</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>http://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>http://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study-level clinical trial data</doc_type>
      <doc_url>http://clinicaltrials.servier.com</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

